MetaCap

IGC Pharma Inc. (IGC)

NYSE: IGCHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.168-0.016 (-8.70%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

IGC stock chart

Technical analysis

Key statistics

All statistics
Market cap
$19.60M
EPS (TTM)
-$0.07
52-week range
0.08 – 0.36
Day range
0.168 – 0.1863
Volume / Avg
500.33K / 615.25K
Beta
—

52-week range

$0.08$0.36

IGC stock today

On Nov 20, IGC ended the session at $0.168, shedding $0.016 (8.70%), versus the S&P 500's 3.70% decline. Shares are 53.3% below their 52-week high of $0.36, set on Dec 10, 2025 and 110.0% above the 52-week low of $0.08, in the middle of the past year's range. IGC is down 40.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 47.5%.

IGC Pharma has posted a net loss over the last twelve months (EPS of -$0.07), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About IGC Pharma

Company profile

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Ram Mukunda
Headquarters
Potomac, MD
Employees
70

Financial highlights

Full financials

In fiscal 2025, IGC Pharma generated $1.3 million in revenue, down 5.5% from fiscal 2024, its first annual decline since 2022. IGC Pharma reported a net loss of $7.1 million, compared with a loss of $13.0 million a year earlier. Gross margin was 48.7% (down from 54.5%) and operating margin -585.8%.

IGC Pharma annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$1.27M$1.34M$911.00K$397.00K$898.00K
Growth-5.50%+47.64%+129.47%-55.79%-77.95%
Net income$-7.12M$-13.00M$-11.51M$-15.02M$-8.81M
EPS (diluted)$-0.09$-0.22——$-0.21

Analyst forecast

Forecast

Consensus (1 analysts)

none

Avg. price target

$6.00+3471.43%

  • Strong buy 0
  • Buy 1
  • Hold 0
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 13, 2026
EPS actual vs est.
$-0.02 vs $-0.02

IGC Pharma peers

Health Care sector
IGC peer companies
CompanyPrice% ChgMarket capCompare
TXMDTherapeuticsMD Inc.1.71-5.52%$19.79Mvs IGC
ACETAdicet Bio Inc.2.14-13.01%$20.03Mvs IGC
RNAZTransCode Therapeutics Inc.1.16-10.77%$20.07Mvs IGC
AARDAardvark Therapeutics Inc.0.9226-7.74%$20.20Mvs IGC
CPHIChina Pharma Holdings Inc.0.4384-13.00%$18.86Mvs IGC
COCPCocrystal Pharma Inc.0.95-2.05%$18.30Mvs IGC
MRKRMarker Therapeutics Inc.1.09-17.42%$18.17Mvs IGC
KTTAPasithea Therapeutics Corp.0.4787-0.48%$17.59Mvs IGC

Indexes, lists and sector

IGC Pharma stock FAQ

What is IGC Pharma's stock price today?

IGC last traded at $0.168 as of Nov 20, 4:00 PM EST, down 8.70% on the day. Prices are delayed at least 15 minutes.

Does IGC Pharma pay a dividend?

No. IGC Pharma does not currently pay a regular cash dividend.

Who is IGC Pharma's CEO?

Mr. Ram Mukunda is the chief executive officer of IGC Pharma Inc., which has about 70 employees.

Has IGC ever split its stock?

Yes. The most recent IGC stock split was a 1-for-10 split on Apr 19, 2013.

What is the IGC 52-week high?

The 52-week high for IGC is $0.36 and the 52-week low is $0.08. The stock is currently 53.3% below its high.

Compare IGC